AC
ELDN icon

Ascend Capital’s Eledon Pharmaceuticals ELDN Stock Holding History

Ascend Capital’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-617
Closed -$1.13M – 164
2015
Q1 		$1.13M Buy
+617
New +$1.36M 0.04% 150

Other funds holding ELDN

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCP
Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ascend Capital's ELDN Position: Q2 2015 in Review

Ascend Capital sold out of Eledon Pharmaceuticals (ELDN) in Q2 2015, closing a stake of 617 shares — an estimated $1.13M sold.

Ascend Capital first reported a position in ELDN in Q1 2015 and held it in 1 quarter. The position peaked at $1.13M in Q1 2015. 50 funds tracked by Wall St. Rank hold ELDN as of Q2 2015.

  • Ascend Capital reported no remaining Eledon Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Ascend Capital sold 617 Eledon Pharmaceuticals shares in Q2 2015, an estimated $1.13M.
  • Ascend Capital first reported a position in Eledon Pharmaceuticals in Q1 2015 and held it in 1 quarter.
  • Ascend Capital's Eledon Pharmaceuticals position peaked at $1.13M in Q1 2015.
  • 50 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2015.

Based on Ascend Capital's 13F filing for Q2 2015, filed 13 Aug 2015.